NKARTA: Recent IP and Promising Results in a Clinical Trial with CD19 CAR- Modified Natural Killer Cells
SOPHIA ANTIPOLIS, France – August 03, 2023 │ Today, immunotherapy is essential in cancer treatment. This field is therefore in full expansion and a lot of innovative therapies are emerging. In 2017, the FDA approval of two CAR-T cells therapies (KYMRIAH™ from Novartis and YESCARTA™ from Kite Pharma, a Gilead company) has enable the development[…]